Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Efficacy and Safety of TF002 in Cutaneous Mastocytosis
The current study will investigate the effects of TF002 on cutaneous mastocytosis or
 cutaneous involvement of systemic mastocytosis as compared to clobetasol proprionate
 (positive control) and a general skin care product without active ingredient targeting
 mastocytosis (negative control) based on clinical effects on Darier´s signs and the
 histological evaluation of mast cell numbers in skin bioptic material.
This is a randomised, double-blind, placebo- and active-controlled study with
 intra-individual comparison of test areas.

 The primary study target is to evaluate the safety and efficacy of TF002 for the treatment of
 cutaneous mastocytosis or systemic mastocytosis with skin involvment. The treatment period of
 14 days was adjusted to the maximum recommended treatment period for the comparator
 Dermoxinale®.

 Since there are no approved therapies for this indication a placebo controlled design was
 chosen.

 There are some reports about transient treatment effects using high potent steroids like
 clobetasol in mastocytosis. This triggered the decision to use Dermoxinale® as positive
 control.

 To validate the clinical scores used in the study, surrogate markers describing the Darier´s
 sign (thermography, volumetric test) will be evaluated optionally.
Inclusion Criteria:

 -  Chronic stable symptomatic maculopapulous cutaneous mastocytosis or systemic
 mastocytosis with involvement of the skin and with positive Darier's Sign

 -  3 comparable skin lesional areas

 -  Otherwise healthy according to physical examination

 -  Informed consent signed and dated

 Exclusion Criteria:

 -  Aggressive systemic mastocytosis

 -  Other dermatological diseases at treated skin site

 -  Known hypersensitivity to study drugs or their components

 -  Mental disorders

 -  Drug or alcohol dependency

 -  Any other chronic or acute illness requiring systemic treatment which might have any
 influence on the outcome of the study in the 4 weeks before start of treatment and
 during the study (investigator's decision).

 -  Immunodeficiency including HIV

 -  Pregnancy or lactation

 -  Participation in another clinical trial within the last 30 days

 -  Malignant skin lesions

 -  Radiation therapy of target areas excluding UV therapy longer then 4 weeks before
 start of study treatment

 -  Dermal comorbidities within the target areas

 -  Any concomitant medication which might influence the study objectives or are known to
 provoke or aggravate mastocytosis